MOBIX LABS, INC shareholders approved Transaction Proposal at the 2023-12-18 meeting.
“Set forth below are the voting results for the Transaction Proposal: For Against Abstain Broker Non-Votes 2,496,408 3,004 0 N/A”
MOBIX LABS, INC — fact timeline
Source-grounded facts extracted from MOBIX LABS, INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MOBIX LABS, INC incurred loan of up to $325,000 with Chavant Capital Partners LLC (the "Sponsor") at 10.0% per annum maturing upon the earlier of (i) the consummation of the Proposed Transaction and (ii) one year from the date of issuance.
“On November 30, 2023, Chavant issued an unsecured note (the “Promissory Note”) in the aggregate principal amount of up to $325,000 to its sponsor, Chavant Capital Partners LLC (the “Sponsor”).”
MOBIX LABS, INC amended Amendment No. 2 with Chavant, Mobix Labs, Merger Sub (effective 2023-11-26).
“Amendment No. 2 to the Business Combination Agreement On November 26, 2023, Chavant entered into Amendment No. 2 (“Amendment No.”
MOBIX LABS, INC received a nasdaq delisting notice notice regarding shareholders (rules 5550(a)(3)).
“the “Hearing”), in connection with the Company’s previously reported failure to maintain a minimum Market Value of Listed Securities (“MVLS”) for the Company’s ordinary shares above the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) and (ii) the Company’s previously reported failure to satisfy Listing Rule 5550(a)(3), which requires the Company to have at least 300 “Public Holders” (as defined in Listing Rule 5005(a)(36)) for continued listing on The Nasdaq Capital Market (the “Minimum Public Holder”
MOBIX LABS, INC received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“the “Hearing”), in connection with the Company’s previously reported failure to maintain a minimum Market Value of Listed Securities (“MVLS”) for the Company’s ordinary shares above the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) and (ii) the Company’s previously reported failure to satisfy Listing Rule 5550(a)(3), which requires the Company to have at least 300 “Public Holders” (as defined in Listing Rule 5005(a)(36)) for continued listing on The Nasdaq Capital Market (the “Minimum Public Holder”
MOBIX LABS, INC received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
“y the Company, which indicated that for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (“MVLS”) for the Company’s ordinary shares was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”) and that the Company had until September 19, 2023 to regain compliance. The Notice states that the Company has not regained compliance with the MVLS Rule within the required 180-day period and that the ordinary shares and the other listed securities of the Company (Nasda”
MOBIX LABS, INC received a nasdaq deficiency notice notice regarding other (rules 5550(a)(3)).
“August 24, 2023, Chavant Capital Acquisition Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it currently does not satisfy Listing Rule 5550(a)(3), which requires the Company to have at least 300 “Public Holders” (as defined in Listing Rule 5005(a)(36)) for continued listing on the Nasdaq Capital Market (the “Minimum Public Holders Rule”). The Notice followed the Company’s communication to the Staff that it was not in compliance with Listing Rule 5550(a)(3)”
MOBIX LABS, INC received a nasdaq deficiency notice notice regarding shareholders (rules 5550(a)(3)).
“August 18, 2023, in response to an inquiry by the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), Chavant Capital Acquisition Corp. (the “Company”) notified the Staff that it currently does not satisfy Listing Rule 5550(a)(3), which requires that the Company have at least 300 “Public Holders” (as defined in Listing Rule 5005(a)(36)) for continued listing on the Nasdaq Capital Market (the “Minimum Public Holders Rule”). The Company is monitoring the number of its Public Holders and will consider options available to it to potentially achieve compliance. Such notification will not”
MOBIX LABS, INC: Amended the Amended and Restated Memorandum and Articles of Association to extend the deadline for initial business combination from July 22, 2023 to January 22, 2024, and to eliminate certain redemption limitations and net tangible asset requirements (effective 2023-07-18).
“On July 18, 2023, Chavant Capital Acquisition Corp. (the “Company” or “Chavant”) held an Extraordinary General Meeting of shareholders to obtain shareholder approval to amend the Company’s Amended and Restated Memorandum and Articles of Association to (i) extend the date by which the Company must consummate an initial business combination from July 22, 2023 to January 22, 2024 (the “Extended Date”) (the “Extension Amendment”) and (ii) eliminate (x) the limitation that the Company shall not redeem the Company’s public shares to the extent that such redemption would cause the Company’s net tangible assets to be less than $5,000,001 and (y) the limitation that the Company shall not consummate a business combination unless the Company has net tangible assets of at least $5,000,001 immediately prior to, or upon consummation of, or any greater net tangible asset or cash requirement that may be contained in the agreement relating to, such business combination (the “Redemption Limitation Amend”
MOBIX LABS, INC shareholders approved Redemption Limitation Amendment Proposal at the 2023-07-18 meeting.
“Set forth below are the voting results for the Redemption Limitation Amendment Proposal: For Against Abstain Broker Non-Votes 2,672,153 843 0 N/A”
MOBIX LABS, INC shareholders approved Extension Amendment Proposal at the 2023-07-18 meeting.
“Set forth below are the voting results for the Extension Amendment Proposal: For Against Abstain Broker Non-Votes 2,669,150 3,846 0 N/A”
MOBIX LABS, INC incurred loan of up to $500,000.00 with Chavant Capital Partners LLC at 10.0% per annum maturing upon the earlier of (i) the consummation of the Proposed Transaction and (ii) one year from the date of issuance.
“On June 22, 2023, Chavant Capital Acquisition Corp., a publicly traded special purpose acquisition company incorporated under the laws of the Cayman Islands (“Chavant”), issued an unsecured note (the “Promissory Note”) in the aggregate principal amount of up to $500,000.00 to its sponsor, Chavant Capital Partners LLC (the “Sponsor”).”
MOBIX LABS, INC amended BCA Amendment with Chavant Capital Acquisition Corp., CLAY Merger Sub II, Inc., and Mobix Labs, Inc. (effective 2023-04-07).
“On April 7, 2023, Chavant Capital Acquisition Corp., a publicly traded special purpose acquisition company incorporated under the laws of the Cayman Islands (“Chavant”), entered into Amendment No. 1 (the “BCA Amendment”) to the previously disclosed Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”), dated November 15, 2022, by and among Chavant, CLAY Merger Sub II, Inc., a Delaware corporation and newly formed, wholly-owned direct subsidiary of Chavant (“Merger Sub”), and Mobix Labs, Inc., a Delaware corporation (the “Company” or “Mobix Labs”).”
MOBIX LABS, INC received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
“March 23, 2023, Chavant Capital Acquisition Corp. (the “Company”) received a notice from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, for the previous 30 consecutive business days, the minimum Market Value of Listed Securities (“MVLS”) for the Company’s ordinary shares was below the $35 million minimum MVLS requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (the “MLVS Rule”). Additionally, as of the date of this Form 8-K, the Company does not meet either of the alternative Nasdaq continued listin”
MOBIX LABS, INC: Extended the date to consummate an initial business combination from January 22, 2023 to July 22, 2023 by amending the Amended and Restated Memorandum and Articles of Association (effective 2023-01-06).
“On January 6, 2023, the Company held an Extraordinary General Meeting of shareholders, to obtain shareholder approval of the extension of the date by which the Company must consummate an initial business combination from January 22, 2023 to July 22, 2023 (the “Extended Date”) by amending the Company’s Amended and Restated Memorandum and Articles of Association (the “Extension Amendment”).”
MOBIX LABS, INC shareholders approved Extension Amendment Proposal at the 2023-01-06 meeting.
“Set forth below are the voting results for the Extension Amendment Proposal: For Against Abstain Broker Non-Votes 2,694,454 18,562 0 0”
MOBIX LABS, INC incurred convertible notes of up to $300,000 with Chavant Capital Partners LLC maturing the earlier of (i) five business days after the closing of the initial business combination and (ii) July 31, 2024.
“issued an unsecured convertible note (the “Promissory Note”) in the aggregate principal amount of up to $300,000 to its sponsor”
MOBIX LABS, INC entered into Promissory Note with Chavant Capital Partners LLC (the Sponsor) valued at up to $300,000 (effective 2023-01-06).
“On January 6, 2023, Chavant Capital Acquisition Corp. (the “Company” or “Chavant”) issued an unsecured convertible note (the “Promissory Note”) in the aggregate principal amount of up to $300,000 to its sponsor, Chavant Capital Partners LLC (the “Sponsor”).”
MOBIX LABS, INC entered into Business Combination Agreement with Chavant Capital Acquisition Corp. valued at 235.0 million USD in shares of Class A Common Stock and Class B Common Stock (effective 2022-11-15).
“Business Combination Agreement As previously announced, on November 15, 2022, Chavant Capital Acquisition Corp., a publicly traded special purpose acquisition company incorporated under the laws of the Cayman Islands (“Chavant”), CLAY Merger Sub II, Inc., a Delaware corporation and newly formed, wholly-owned direct subsidiary of Chavant (“Merger Sub”), and Mobix Labs, Inc., a Delaware corporation (the “Company” or “Mobix Labs”), entered into a business combination agreement (the “Business Combination Agreement”), pursuant to which, among other things, Merger Sub will merge with and into Mobix Labs, with Mobix Labs surviving the merger as a wholly-owned direct subsidiary of Chavant (the “Merger” and, together with the other transactions related thereto, the “Proposed Transaction”).”
Bernhard Stapp was appointed as Director at MOBIX LABS, INC.
“on July 19, 2021, Patrick Ennis, Karen Kerr and Bernhard Stapp (collectively, the “Directors”) were appointed to the board of directors of the Company (the “Board”).”
Karen Kerr was appointed as Director at MOBIX LABS, INC.
“on July 19, 2021, Patrick Ennis, Karen Kerr and Bernhard Stapp (collectively, the “Directors”) were appointed to the board of directors of the Company (the “Board”).”
Patrick Ennis was appointed as Director at MOBIX LABS, INC.
“on July 19, 2021, Patrick Ennis, Karen Kerr and Bernhard Stapp (collectively, the “Directors”) were appointed to the board of directors of the Company (the “Board”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.